Gout and Crystal Arthropathy

📋 Key Information Summary

📋

Gout affects approximately 6.8% of Australian men and 2.0% of women, with significantly higher prevalence in Aboriginal and Torres Strait Islander peoples and those of Māori or Pacific Islander descent.
Acute gout flare should be treated within 24 hours of symptom onset; colchicine (low-dose regimen), NSAIDs, or oral/intra-articular corticosteroids are all first-line options.
Low-dose colchicine regimen: 0.5 mg twice daily for up to 3–5 days after flare onset — avoid old high-dose loading regimens due to toxicity risk.
Urate-lowering therapy (ULT) should be considered after ≥2 flares per year, tophi, radiographic damage, or urate nephrolithiasis; target serum urate <0.36 mmol/L (or <0.30 mmol/L if tophi present).
Allopurinol is first-line ULT; start at 50–100 mg daily, titrate by 50–100 mg every 2–4 weeks to serum urate target; requires renal dose adjustment.
HLA-B*5801 testing is MANDATORY before initiating allopurinol in patients of South-East Asian, African American, or Han Chinese descent due to severe cutaneous adverse reaction (SCAR) risk.
Febuxostat is second-line ULT for allopurinol-intolerant patients; PBS Authority Required; consider cardiovascular risk (CARES trial findings).
Prophylaxis with low-dose colchicine (0.5 mg once daily) or low-dose NSAID is essential when commencing ULT to prevent flares triggered by urate mobilisation.
CPPD (calcium pyrophosphate deposition) presents as acute pseudogout or chronic pyrophosphate arthropathy; diagnosis requires synovial fluid analysis showing weakly positively birefringent rhomboid crystals.
Dietary modification (reduce purine-rich foods, alcohol, fructose-sweetened beverages; increase dairy intake) and weight management are important adjuncts to pharmacotherapy.
ATSI communities experience gout at higher rates with earlier onset, more tophaceous disease, and significant barriers to specialist access in remote areas.
Asymptomatic hyperuricaemia does not require treatment; ULT is indicated only for symptomatic gout or specific clinical scenarios (urate nephrolithiasis, tumour lysis prophylaxis).

Introduction & Australian Epidemiology

Gout is the most common form of inflammatory arthritis in Australia, resulting from the deposition of monosodium urate (MSU) crystals in joints, soft tissues, and kidneys. It represents a significant and growing burden on the Australian healthcare system, with prevalence increasing in parallel with rising rates of metabolic syndrome, obesity, and chronic kidney disease.

The Australian Institute of Health and Welfare (AIHW) estimates that gout affects approximately 6.8% of Australian men and 2.0% of women, with a marked increase in prevalence with age — exceeding 15% in men over 70 years. Aboriginal and Torres Strait Islander peoples experience gout at 1.5–2 times the rate of non-Indigenous Australians, with earlier onset and more severe disease including tophaceous gout.

Crystal arthropathy encompasses two major conditions: gout (monosodium urate crystal deposition) and calcium pyrophosphate deposition (CPPD) disease, historically termed pseudogout. Both conditions share overlapping risk factors including age, metabolic disease, and chronic kidney disease, and may coexist in the same patient.

The economic burden is substantial: gout accounts for over 500,000 general practice consultations annually in Australia, with significant direct costs from pharmaceuticals, emergency department presentations, and indirect costs from work disability.

Pathophysiology

Gout — Monosodium Urate Crystal Deposition

Uric acid is the end product of purine metabolism, generated by xanthine oxidase. Humans lack uricase, resulting in higher serum urate concentrations compared with other mammals. When serum urate exceeds the saturation point (~0.36 mmol/L at physiological pH and temperature), MSU crystals may nucleate and deposit in synovial fluid, cartilage, tendons, and periarticular soft tissues.

The acute gout flare is triggered by innate immune recognition of deposited MSU crystals. Monocytes and synoviocytes phagocytose crystals, activating the NLRP3 inflammasome and triggering release of interleukin-1β (IL-1β). This drives neutrophil recruitment, intense local inflammation, and the characteristic severe pain, swelling, and erythema.

⚠️

Key concept: Asymptomatic hyperuricaemia is NOT gout. Crystal deposition occurs over years before clinical flares manifest. Conversely, some patients with normal-range serum urate develop gout due to local factors (temperature, pH) favouring crystal nucleation.

CPPD — Calcium Pyrophosphate Deposition

CPPD results from deposition of calcium pyrophosphate dihydrate (CPP) crystals in articular cartilage (chondrocalcinosis) and periarticular structures. The pathogenesis involves excess pyrophosphate generation by chondrocytes (via ectonucleotide pyrophosphatase/phosphodiesterase activity) combined with elevated local calcium concentrations. CPPD is strongly associated with ageing, osteoarthritis, metabolic diseases (hyperparathyroidism, haemochromatosis, hypomagnesaemia, hypophosphatasia), and prior joint trauma.

Acute Gout Flare

Clinical Presentation

The acute gout flare typically presents as a monoarticular or oligoarticular inflammatory arthritis with rapid onset (reaching maximum intensity within 6–24 hours). The first metatarsophalngeal joint (podagra) is affected in approximately 50% of first episodes and 90% of patients at some point. Other commonly involved joints include the midfoot, ankle, knee, wrist, and small joints of the hand.

Characteristic features include:

Severe pain — often described as the "worst pain ever experienced"
Erythema and warmth of the overlying skin (may mimic cellulitis)
Marked swelling with loss of joint landmarks
Low-grade fever and systemic malaise may accompany severe flares
Desquamation of skin as flare resolves (peeling sign)

⚠️

Sepsis mimicry: Acute gout can closely mimic septic arthritis. In any hot, swollen joint, perform joint aspiration BEFORE commencing anti-inflammatory therapy to exclude septic arthritis. Simultaneous gout and septic arthritis occurs in 1–2% of cases.

Diagnosis

Definitive diagnosis requires identification of negatively birefringent needle-shaped MSU crystals in synovial fluid or tophus aspirate under polarised light microscopy. In clinical practice, a presumptive diagnosis may be made based on characteristic clinical features, particularly in the context of known hyperuricaemia, tophi, or previous confirmed episodes.

Feature	Gout (MSU)	CPPD	Septic Arthritis
Crystal morphology	Needle-shaped, negatively birefringent	Rhomboid, weakly positively birefringent	No crystals; positive Gram stain/culture
Classic joint	1st MTP, midfoot, ankle	Knee, wrist, 2nd/3rd MCP	Knee (most common), hip
Onset	Rapid (6–24 h)	Rapid (hours–days)	Rapid
WCC (synovial fluid)	>2,000/µL, neutrophil-predominant	>2,000/µL, neutrophil-predominant	>50,000/µL (often >100,000)
Treatment	Colchicine, NSAIDs, steroids	NSAIDs, intra-articular steroids, colchicine	Urgent IV antibiotics + drainage

Management of the Acute Flare

Treatment should be initiated as early as possible, ideally within 24 hours of symptom onset. Choice of agent depends on patient comorbidities, renal function, and concurrent medications.

First-Line Therapies

💊

Colchicine (low-dose regimen)

Colgout® · Generic · Anti-inflammatory

Adult dose 0.5 mg PO twice daily (NOT high-dose loading); continue for 3–5 days or until flare resolves. Maximum 3 tablets (1.5 mg) total on day 1.

Paediatric dose Not established for gout. Juvenile gout: specialist guidance required.

Renal adjustment eGFR 10–50: max 0.5 mg daily. eGFR <10: avoid. Do NOT use with CYP3A4 inhibitors or P-glycoprotein inhibitors.

Hepatic adjustment Avoid in severe hepatic impairment.

PBS status ✔ PBS General Benefit

💊

Naproxen

Naprosyn® · Generic · NSAID

Adult dose 750 mg PO stat, then 250 mg TDS until flare resolves (typically 5–7 days). Take with food and PPI if GI risk.

Renal adjustment Avoid if eGFR <30. Use with caution eGFR 30–60.

PBS status ✔ PBS General Benefit

💊

Indomethacin

Indocid® · NSAID

Adult dose 50 mg PO TDS for 3–5 days, then reduce to 25 mg TDS until flare resolves.

PBS status ✔ PBS General Benefit

💊

Prednisolone

Solone® · Generic · Corticosteroid

Adult dose 30–35 mg PO daily for 5 days then cease (or taper over 7–10 days if longer course needed). No dose taper required for ≤5 days.

Renal adjustment No adjustment required — preferred in CKD when NSAIDs/colchicine contraindicated.

PBS status ✔ PBS General Benefit

Intra-articular Corticosteroid Injection

For monoarticular or oligoarticular flares, intra-articular corticosteroid injection (e.g., methylprednisolone 40–80 mg or triamcinolone 20–40 mg depending on joint size) provides rapid and effective relief, particularly when systemic therapies are contraindicated. Ultrasound guidance improves accuracy for deeper joints.

🚨

CRITICAL — Do NOT start or stop ULT during an acute flare. Changing ULT doses during an acute flare prolongs and worsens the flare. If already on ULT, continue at the same dose. ULT initiation or dose adjustment should occur 2–4 weeks after flare resolution.

IL-1 Inhibitors (Refractory Cases)

Anakinra (IL-1 receptor antagonist) 100 mg SC daily for 3–5 days may be considered in patients with contraindications or inadequate response to all first-line agents. It is not PBS-listed for gout but may be used off-label in specialist settings. Canakinumab is TGA-approved for gout but is not PBS-listed.

Chronic Tophaceous Gout

Chronic tophaceous gout represents the most severe end of the gout spectrum, characterised by visible or palpable tophi (aggregates of MSU crystals surrounded by a granulomatous inflammatory response), chronic inflammatory arthritis, and structural joint damage. It typically develops after 5–10 years of inadequately treated or untreated gout, though it may present earlier in patients with CKD, myeloproliferative disorders, or on cyclosporine therapy.

Clinical Features

Tophi: firm nodules on extensor surfaces of fingers, olecranon bursae, Achilles tendons, pinnae of ears, and periarticular regions
Chronic polyarticular joint inflammation with reduced range of motion
Radiographic erosions with overhanging edges (rat-bite erosions) and relative preservation of joint space
Tophus ulceration through skin with chalky white discharge
Secondary osteoarthritic changes
Urate nephrolithiasis and chronic urate nephropathy

Management Principles

The cornerstone of chronic tophaceous gout management is sustained serum urate lowering below 0.30 mmol/L (lower than the standard target of 0.36 mmol/L) to promote gradual tophus dissolution. Key principles include:

Start ULT at low dose with gradual up-titration to minimise flare risk
Mandatory flare prophylaxis with low-dose colchicine or low-dose NSAID for first 3–6 months of ULT (longer if tophi persist)
Regular serum urate monitoring every 2–4 weeks during titration, then every 6 months once stable
Combination therapy (xanthine oxidase inhibitor + uricosuric) may be required for refractory hyperuricaemia
Patient education regarding medication adherence — ULT is typically lifelong
Tophus resolution may take 6–36 months of sustained urate lowering

ℹ️

Treat-to-target approach: Australian and international guidelines recommend a treat-to-target strategy for ULT, aiming for serum urate <0.36 mmol/L (or <0.30 mmol/L with tophi). This requires regular monitoring and dose adjustment — fixed-dose prescribing without monitoring leads to suboptimal outcomes.

CPPD (Pseudogout)

Calcium pyrophosphate deposition (CPPD) disease encompasses a spectrum of clinical presentations unified by the deposition of calcium pyrophosphate dihydrate crystals in articular and periarticular tissues. CPPD is strongly age-related, affecting up to 25–50% of individuals over 80 years, and is visible as chondrocalcinosis on plain radiographs.

Clinical Presentations

Acute

Acute Pseudogout

Acute monoarticular or oligoarticular arthritis — classically the knee or wrist. Clinically indistinguishable from acute gout without crystal analysis. May be triggered by medical illness, surgery, or intra-articular hyaluronate injection.

Setting: ED or acute rheumatology

Chronic

Chronic Pyrophosphate Arthropathy

Chronic inflammatory arthropathy mimicking osteoarthritis or rheumatoid arthritis. Affects large joints (knees, wrists, shoulders, hips). Progressive joint degeneration with chondrocalcinosis on imaging.

Setting: Rheumatology outpatient

Systemic

Systemic CPPD / Crowned Dens Syndrome

Severe neck pain and stiffness with CPPD around the odontoid process. May cause fever and elevated inflammatory markers, mimicking meningitis or giant cell arteritis. CT imaging shows peri-odontoid calcification.

Setting: Emergency — exclude serious differential diagnoses

Diagnosis

Definitive diagnosis: identification of weakly positively birefringent rhomboid CPP crystals in synovial fluid by compensated polarised light microscopy. Chondrocalcinosis on radiograph (calcification of hyaline cartilage or fibrocartilage) supports the diagnosis but is not specific.

Investigations for Underlying Metabolic Causes

CPPD in patients under 55 years, polyarticular involvement, or unusual joint distribution warrants investigation for underlying metabolic diseases:

Serum calcium, phosphate, alkaline phosphatase, magnesium, ferritin, transferrin saturation
Parathyroid hormone (hyperparathyroidism)
Iron studies (haemochromatosis — HFE gene testing if elevated)
Serum magnesium (hypomagnesaemia)
Thyroid function tests
Consider hypophosphatasia (low alkaline phosphatase) — rare but important

Treatment

No disease-modifying therapy for CPPD currently exists. Management is directed at symptom relief:

Acute pseudogout: NSAIDs (first-line), intra-articular corticosteroid injection, colchicine (0.5 mg BD), or short course oral prednisolone
Chronic pyrophosphate arthropathy: Paracetamol, low-dose NSAIDs, physiotherapy, intra-articular corticosteroid injections, joint replacement for end-stage disease
Prophylaxis for recurrent acute pseudogout: Low-dose colchicine 0.5 mg daily; evidence is extrapolated from gout literature
Treat underlying metabolic cause: Correction of hyperparathyroidism, haemochromatosis, or hypomagnesaemia may reduce recurrence

ℹ️

No role for ULT in CPPD: Urate-lowering therapy has no role in CPPD management. Allopurinol does not affect CPP crystal deposition. A common error is treating CPPD as gout — always confirm the crystal type.

Urate-Lowering Therapy (ULT)

Indications for ULT Initiation

ULT should be considered in patients with:

≥2 gout flares per year
Presence of tophi (clinical or imaging-detected)
Radiographic evidence of gout-related joint damage
Urate nephrolithiasis
First flare with additional risk factors (eGFR <60, urate >0.54 mmol/L, young age at onset)
CKD stage 3+ with any gout flare

⚠️

Asymptomatic hyperuricaemia: ULT is NOT indicated for asymptomatic hyperuricaemia alone, even if serum urate is markedly elevated. Treatment is initiated only for symptomatic gout or specific indications (urate nephrolithiasis, tumour lysis prophylaxis, Lesch-Nyhan syndrome).

Allopurinol — First-Line ULT

💊

Allopurinol

Zyloprim® · Allosig® · Progout® · Xanthine oxidase inhibitor

Starting dose 50–100 mg PO once daily. Start at 50 mg if eGFR <60.

Titration Increase by 50–100 mg every 2–4 weeks based on serum urate. Usual maintenance: 200–600 mg daily (max 900 mg in normal renal function).

Renal adjustment eGFR 30–60: start 50 mg, max ~300 mg. eGFR <30: start 50 mg, max ~200 mg. Titrate based on serum urate, not arbitrary dose limits.

Hepatic adjustment Dose reduction recommended in hepatic impairment. Monitor LFTs.

Key interactions Azathioprine/6-mercaptopurine (absolute contraindication — fatal toxicity). Warfarin (increased INR). ACE inhibitors (increased hypersensitivity risk).

PBS status ✔ PBS General Benefit

🚨

Allopurinol hypersensitivity syndrome (AHS): Potentially fatal severe cutaneous adverse reactions (SCAR) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can occur with allopurinol. Risk factors: HLA-B*5801 positivity (particularly in South-East Asian, Han Chinese, African American populations), CKD, concurrent thiazide diuretics, and rapid dose escalation. See HLA-B*5801 section below.

Febuxostat — Second-Line ULT

💊

Febuxostat

Adenuric® · Xanthine oxidase inhibitor (non-purine selective)

Adult dose 80 mg PO once daily. May increase to 120 mg daily if serum urate not at target after 2–4 weeks.

Renal adjustment No dose adjustment required in mild-to-moderate CKD (eGFR ≥30). Limited data in eGFR <30 — use with caution.

Hepatic adjustment No dose adjustment in mild-to-moderate hepatic impairment. Avoid in severe hepatic impairment.

Key interactions Azathioprine/6-mercaptopurine (absolute contraindication). Theophylline (monitor levels).

PBS status ✔ PBS Authority Required — Authority required for patients in whom allopurinol is contraindicated, not tolerated, or has failed after adequate trial at maximum tolerated dose.

⚠️

Cardiovascular caution — CARES trial: The CARES trial (2018) demonstrated increased cardiovascular mortality with febuxostat compared with allopurinol in patients with pre-existing cardiovascular disease. Febuxostat should generally be reserved for patients who cannot take allopurinol. In patients with established CVD, the risk-benefit ratio should be carefully considered and documented.

Uricosuric Agents

💊

Probenecid

Proben® · Uricosuric

Adult dose 500 mg PO twice daily, increase to 1 g twice daily after 1 week if needed. Maintain hydration (≥2 L fluid daily).

Contraindications Urolithiasis, urate overproduction (urate >0.60 mmol/L), severe renal impairment (eGFR <30), blood dyscrasias.

PBS status ✔ PBS General Benefit

Flare Prophylaxis During ULT Initiation

Mandatory when starting or up-titrating ULT — continue for at least the first 3–6 months (longer if tophi present or flares continue):

🛡️

Colchicine prophylaxis

Colgout® · Flare prevention

Dose 0.5 mg PO once daily. If eGFR <45: 0.5 mg every 2nd day. If eGFR <15: avoid.

Duration Minimum 3–6 months after reaching urate target. Continue until tophi resolved if present.

PBS status ✔ PBS General Benefit

🛡️

Naproxen prophylaxis (alternative)

Naprosyn® · Flare prevention

Dose 250 mg PO twice daily. Consider PPI co-prescription for GI protection.

PBS status ✔ PBS General Benefit

HLA-B*5801 Testing

🚨

MANDATORY HLA-B*5801 screening: HLA-B*5801 testing is mandatory before initiating allopurinol in patients of South-East Asian, Han Chinese, Korean, Thai, or African American descent. This is a Medicare-rebatable test (MBS item 71162) in Australia. Allopurinol must NOT be commenced if the test is positive.

Rationale

HLA-B*5801 is a strong genetic risk factor for allopurinol-induced severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The allele frequency varies significantly by ethnicity:

Population	HLA-B*5801 Allele Frequency	Testing Recommendation
Han Chinese	6–8%	Mandatory
Korean	6–8%	Mandatory
Thai	6–12%	Mandatory
South-East Asian (general)	2–8%	Mandatory
African American	4–8%	Mandatory
Māori / Pacific Islander	2–4%	Strongly recommended
ATSI populations	Data limited — consult local guidance	Consider testing
European / Caucasian	<1%	Not routinely required

Australian Practice Points

MBS item 71162 provides Medicare rebate for HLA-B*5801 genotyping — no out-of-pocket cost to patients when clinically indicated
Testing is performed on a standard blood sample — results typically available within 7–14 business days
If HLA-B*5801 positive: allopurinol is contraindicated. Use febuxostat (PBS Authority Required) or probenecid as alternatives
If HLA-B*5801 negative: allopurinol may be commenced with standard precautions (low starting dose, gradual titration)
HLA-B*5801 testing is not required for febuxostat or probenecid
Additional risk factors for SCAR: CKD (especially eGFR <30), concurrent thiazide diuretics, rapid dose up-titration, female sex

✅

Quality improvement: All Australian patients starting allopurinol should be asked about their ethnic background to determine if HLA-B*5801 testing is indicated. Given Australia's multicultural population, clinicians should maintain a low threshold for testing. Document the result in the patient's medical record and allergy list if positive.

Diet & Lifestyle Modifications

Dietary and lifestyle modifications are important adjuncts to pharmacotherapy in gout management. While dietary measures alone are rarely sufficient to normalise serum urate in patients with established gout, they can reduce flare frequency and are essential for addressing the metabolic comorbidities that frequently coexist.

Dietary Recommendations

🟢 Foods to Increase

Low-fat dairy products (contain orotic acid, which promotes renal urate excretion)
Cherries and cherry extract (associated with reduced flare risk — observational data)
Coffee (regular consumption associated with lower serum urate — not decaf)
Vitamin C supplementation (500 mg daily modestly reduces serum urate by ~0.05 mmol/L)
Plant-based proteins (legumes, tofu) — lower risk than animal purines
Complex carbohydrates, whole grains

🔴 Foods to Reduce or Avoid

Organ meats (liver, kidney, sweetbreads — very high purine content)
Shellfish, anchovies, sardines
Red meat (limit to small portions)
Beer and spirits (beer contains guanosine — a purine; spirits increase urate)
Sugar-sweetened beverages and foods with high-fructose corn syrup
Excessive fruit juice (fructose load)

Alcohol

Alcohol is a significant modifiable risk factor for gout. Beer has the strongest association due to its high guanosine (purine) content and the metabolic effects of ethanol on renal urate excretion. Spirits increase gout risk, while moderate wine consumption appears to have a weaker association. Recommendation: minimise alcohol, particularly beer and spirits. If consuming alcohol, limit to ≤2 standard drinks per day with at least 2 alcohol-free days per week.

Weight Management

Obesity is one of the strongest modifiable risk factors for gout. Weight loss (even 5–10% of body weight) reduces serum urate, decreases flare frequency, and improves metabolic comorbidities. Extreme fasting or crash dieting should be avoided as ketosis increases serum urate and may trigger flares.

Hydration

Maintaining adequate hydration (≥2 litres of water daily) promotes renal urate excretion and reduces risk of urate nephrolithiasis. This is particularly important for patients on uricosuric therapy (probenecid).

Exercise

Regular moderate exercise improves metabolic health, aids weight management, and may independently reduce gout risk. Avoid dehydration during exercise. High-intensity exercise that causes tissue breakdown may transiently increase serum urate.

Medication Review

Common medications that raise serum urate and should be reviewed:

Thiazide and loop diuretics — consider alternatives (e.g., losartan, which has mild uricosuric properties)
Low-dose aspirin — generally continued for cardiovascular indications despite effect on urate
Ciclosporin — causes both hyperuricaemia and reduced renal urate excretion
Pyrazinamide — used in tuberculosis treatment
Ethambutol
Tacrolimus
Niacin (vitamin B3)

✅

Losartan advantage: Among antihypertensives, losartan has a mild uricosuric effect and is the preferred ACE inhibitor/ARB in patients with gout and hypertension. Amlodipine (calcium channel blocker) is also urate-neutral. Avoid thiazides where possible.

Monitoring

Serum Urate Monitoring

Baseline

Serum urate, FBC, LFTs, eGFR, urinalysis before starting ULT

Every 2–4 weeks

Serum urate during ULT titration — adjust dose to reach target <0.36 mmol/L

At target

Serum urate every 6 months once stable at target for ≥12 months

Ongoing

Annual FBC, LFTs, eGFR, urate. Monitor for allopurinol side effects (rash, cytopenias)

Assessing Tophus Resolution

Clinical examination for tophi at each visit — document size, number, and location
Ultrasound or dual-energy CT (DECT) may be used for objective tophi quantification
Tophus resolution typically requires 6–36 months of sustained urate below 0.30 mmol/L

Flare Frequency Tracking

Maintain a flare diary. A reduction in flare frequency is one of the most clinically meaningful outcomes of successful ULT. Patients should be counselled that flares may increase in the first 3–6 months of ULT as previously deposited crystals mobilise — this does not indicate treatment failure.

Special Populations

🤰 Pregnancy & Breastfeeding

Acute flare: Intra-articular corticosteroid injection is preferred. Oral prednisolone is acceptable (category A in Australia). Avoid NSAIDs especially in the third trimester (premature ductus arteriosus closure). Colchicine: avoid if possible; limited data but some centres permit short courses.

ULT: Allopurinol is category D — avoid in pregnancy and breastfeeding. Febuxostat: category D, avoid. Probenecid: category B2, may be used if ULT essential.

Breastfeeding: Allopurinol and metabolite (oxipurinol) excreted in breast milk — avoid during breastfeeding.

👶 Paediatrics

Paediatric gout is rare and usually secondary to inborn errors of purine metabolism (e.g., Lesch-Nyhan syndrome — HGPRT deficiency), glycogen storage diseases, or chronic kidney disease.

Acute flare: NSAIDs (ibuprofen 5–10 mg/kg/dose TDS) or short-course oral prednisolone. Avoid colchicine in children under 5.

ULT: Allopurinol 10 mg/kg/day in 3 divided doses (max 400 mg/day) for Lesch-Nyhan syndrome. Specialist paediatric rheumatology or metabolic medicine supervision required.

Adolescent gout: Increasing recognition linked to obesity and metabolic syndrome. Management follows adult guidelines with age-appropriate dosing.

👴 Elderly

Higher prevalence — gout affects >15% of men over 70 years in Australia.

Colchicine toxicity risk: Increased risk in elderly, especially with CKD or concurrent CYP3A4/P-gp inhibitors (verapamil, diltiazem, clarithromycin, cyclosporine). Use lower doses.

NSAIDs: Use with extreme caution — GI bleeding, renal impairment, cardiovascular risk. Prefer short-course oral prednisolone as alternative.

Polypharmacy: Review medications — diuretics, low-dose aspirin, ciclosporin all increase urate.

Allopurinol: Start at 50 mg daily regardless of eGFR; titrate slowly. CKD is common in elderly — renal dose adjustment essential.

🫘 Renal Impairment (CKD)

CKD increases gout risk due to reduced renal urate excretion. CKD stage 3+ is a strong indication for ULT after any gout flare.

Allopurinol: Start 50 mg daily if eGFR <60. Titrate to serum urate target — do NOT impose arbitrary maximum doses; some patients require higher doses than guidelines suggest. Monitor closely for hypersensitivity.

Febuxostat: No dose adjustment needed for eGFR ≥30. Limited data below eGFR 30. Preferred over allopurinol if allopurinol not tolerated or if HLA-B*5801 positive.

Colchicine: Reduce dose: eGFR 10–50: 0.5 mg daily; eGFR <10: avoid. Accumulation risk — monitor for myopathy and neuropathy.

NSAIDs: Avoid in eGFR <30. Use with caution eGFR 30–60. Prednisolone is preferred.

Probenecid: Ineffective and contraindicated if eGFR <30.

🫁 Hepatic Impairment

Allopurinol: Dose reduction recommended. Monitor LFTs — hepatotoxicity is a rare but serious adverse effect. Discontinue if transaminases rise >3× ULN.

Febuxostat: No dose adjustment in mild-moderate impairment. Avoid in severe hepatic impairment (Child-Pugh C).

Acute flare management: Colchicine hepatically metabolised — use with caution. Prednisolone generally safe. Avoid NSAIDs if cirrhosis with portal hypertension.

🛡️ Immunocompromised

Transplant patients: Ciclosporine and tacrolimus both increase serum urate and reduce renal excretion. Gout is common post-transplant.

Drug interactions critical: Allopurinol inhibits xanthine oxidase — azathioprine and 6-mercaptopurine metabolism depends on xanthine oxidase. Combination is CONTRAINDICATED (fatal pancytopenia risk). If azathioprine must be continued, use mycophenolate as alternative, or febuxostat with extreme caution (also inhibits XO).

Probenecid: May be used as alternative to XOIs in transplant patients on azathioprine. Interacts with some antibiotics (penicillins, cephalosporins).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology

ATSI peoples experience gout at 1.5–2 times the prevalence of non-Indigenous Australians, with earlier onset, more frequent flares, and higher rates of tophaceous disease. This is driven by higher rates of CKD, metabolic syndrome, and obesity — all major comorbidities in ATSI communities.

HLA-B*5801

HLA-B*5801 data in ATSI populations are limited. Given the mixed ancestry of many ATSI individuals and the potentially devastating consequences of SCAR, clinicians should consider HLA-B*5801 testing before allopurinol in ATSI patients. Consult with local genetics services if uncertain.

Remote & rural access

Specialist rheumatology services are extremely limited in remote and very remote Australia. Primary care providers in Aboriginal Community Controlled Health Organisations (ACCHOs) are often the sole providers. Telehealth rheumatology consultations (MBS items 91822, 91823) are essential for specialist input. Point-of-care urate testing may be available through some ACCHOs.

CKD burden

CKD prevalence in ATSI communities is 2–3 times higher than non-Indigenous Australians (AIHW). This directly impacts gout management: higher prevalence of gout, more renal dose adjustments needed, greater risk of colchicine and allopurinol toxicity. eGFR must be monitored closely and medication doses adjusted.

Medication adherence

ULT (especially allopurinol) requires sustained daily adherence and regular monitoring — a significant challenge in remote communities with limited access to pathology services. Blister-packing of medications, community pharmacy support, and Aboriginal Health Worker–facilitated medication management improve adherence.

Dietary considerations

Access to fresh fruit, vegetables, and low-fat dairy is limited in many remote communities (food security). Expensive imported foods may be replaced by cheaper processed alternatives high in purines and fructose. Culturally appropriate dietary advice developed in partnership with community is essential — avoid paternalistic approaches.

Cultural safety

Engagement with local Aboriginal Health Workers and Elders improves health literacy and treatment acceptance. Use of plain language, Aboriginal English where appropriate, and visual aids supports understanding. Respect for family and community decision-making processes. Where possible, management should occur through ACCHOs with integrated chronic disease management programmes.

PBS safety net

ATSI patients are eligible for the PBS Co-payment Reduction (Closing the Gap PBS co-payment measure) — reducing out-of-pocket costs for ULT and other medications. Ensure patients are registered for CTG PBS co-payment through their pharmacy. This significantly improves affordability of ongoing ULT.

📚 References

1. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661-667. doi:10.1136/annrheumdis-2013-204463
2. Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2012;42(9):997-1007. doi:10.1111/j.1445-5994.2012.02835.x
3. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707
4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. 2020;72(6):744-760. doi:10.1002/acr.24180
5. Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose optimization with serum urate target to treat gout in the New Zealand health system (ALLO): a study protocol. BMC Musculoskelet Disord. 2020;21(1):45. doi:10.1186/s12891-020-3052-6
6. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout (CARES trial). N Engl J Med. 2018;378(13):1200-1210. doi:10.1056/NEJMoa1710895
7. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134-4139. doi:10.1073/pnas.0409500102
8. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-1855. doi:10.1016/S0140-6736(21)00569-9
9. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium py